Myofascial Release in Patients with Chronic Obstructive Pulmonary Disease

Launched by CARDENAL HERRERA UNIVERSITY · Feb 6, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called myofascial release in people with chronic obstructive pulmonary disease (COPD). Myofascial release is a type of therapy that focuses on relieving tension in the muscles and connective tissues. The goal of the study is to see if this therapy can help improve breathing and overall well-being in patients with COPD.

To qualify for the trial, participants should be between the ages of 65 and 75 and must have COPD, which means they have difficulty breathing. Specifically, their lung function needs to be below certain levels, which will be measured during the screening process. However, individuals who have had recent surgery on their spine or abdomen, have certain allergies or systemic diseases, or have previously received myofascial release treatment will not be eligible. Participants can expect to receive the myofascial release therapy and be monitored for its effects on their condition. This trial is not yet recruiting, so interested individuals will need to wait for further updates.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • COPD;
• • Forced expiratory volume in the first second (FEV1) \< 80%;
• • FEV1/Forced vital capacity (FVC) \< 70%;
• • Maximal inspiratory pressure (MIP) \< 70%.
• Exclusion Criteria:
• • Recent (6 months) spine or abdominal surgery;
• • Allergic status of any kind;
• • systemic diseases (rheumatic, infectious conditions, febrile state, vascular alterations, endocrine diseases including diabetes, metabolic, and neoplastic syndromes);
• • neuromuscular or neurological injuries;
• • previous myofascial release treatment.